Brief: Dermapharm Confirms 2026 Forecast
25/08/2026 06:22
BRIEF-Dermapharm Confirms 2026 Forecast Aug 25 (Reuters) - Dermapharm Holding SE DMPG.DE:
DERMAPHARM HOLDING SE - 2026 FORECAST CONFIRMED
DERMAPHARM HOLDING SE - H1 GROUP REVENUE INCREASES BY 2.9% TO €591.0 MILLION
DERMAPHARM HOLDING SE - H1 ADJUSTED EBITDA GROWS BY 10.3% TO €163.2 MILLION
DERMAPHARM HOLDING SE - H1 ADJUSTED EBITDA MARGIN IMPROVES TO 27.6%
Further company coverage: DMPG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit